Frequencies of inherited organic acidurias and disorders of mitochondrial fatty acid transport and oxidation in Germany
- 9 January 2004
- journal article
- research article
- Published by Springer Nature in European Journal of Pediatrics
- Vol. 163 (2) , 76-80
- https://doi.org/10.1007/s00431-003-1246-3
Abstract
The lack of epidemiological data on the frequency and/or burden of organic acidurias (OA) and mitochondrial fatty acid transport and oxidation disorders (mtFATOD) is one reason for hesitation to expand newborn screening (NBS) by tandem mass spectrometry (MS-MS). From 1999 to 2000, the frequency of ten potentially treatable OA and mtFATOD was assessed by active nation-wide surveillance on cases presenting with clinical symptoms using the German Paediatric Surveillance Unit (ESPED) system. Case ascertainment was complemented by a second independent source: 3-monthly inquiries in the metabolic laboratories performing secondary selected screening for OA and mtFATOD. Frequency estimates for clinically symptomatic cases older than 7 days in a birth cohort of 844,575 conventionally screened children was compared to the frequency found in a cohort of 382,247 screened by MS-MS in Bavaria and Baden-Württemberg. The overall frequency of the ten conditions considered was 1:8,000 (95% CI 1:11,000–1:6,000) by MS-MS as compared to 1:23,000 (95% CI 1:36,000–1:17,000) in symptomatic cases presenting mainly with metabolic crisis. The contributions of medium-chain acyl-CoA dehydrogenase deficiency (MCADD), other mtFATOD and OA were 29, 4 and 13 among the 46 cases identified by MS-MS, and 19, 1 and 13 among the 33 clinically symptomatic cases, respectively. Acute metabolic crisis, with a lethal outcome in four patients, was reported for 22/33 clinically symptomatic cases. No clinically symptomatic cases were reported from cohorts with screened by MS-MS. Conclusion: ten potentially treatable organic acidurias and mitochondrial fatty acid transport and oxidations disorders were more common than phenylketonuria with organic acidurias accounting for 28% of the cases detected by newborn screening and 39% of the cases identified on high risk screening. These conditions were related to considerable morbidity and mortality. Considerations for their inclusion in expanded newborn screening programmes might be warranted.Keywords
This publication has 9 references indexed in Scilit:
- Screening for inherited metabolic disease in newborn infants using tandem mass spectrometryBMJ, 2002
- Neonatal screening for medium-chain acyl-CoA dehydrogenase deficiencyThe Lancet, 2001
- Outcome of medium chain acyl-CoA dehydrogenase deficiency after diagnosisArchives of Disease in Childhood, 1999
- Newborn Screening by Tandem Mass Spectrometry: A New EraClinical Chemistry, 1998
- Prospective surveillance study of medium chain acyl-CoA dehydrogenase deficiency in the UKArchives of Disease in Childhood, 1998
- Evaluating newborn screening programmes based on dried blood spots: future challenges.British Medical Bulletin, 1998
- Newborn screening for inborn errors of metabolism: a systematic review.1997
- Ascertainment Corrected Rates: Applications of Capture-Recapture MethodsInternational Journal of Epidemiology, 1993
- Intellectual performance of children with maple syrup urine diseaseEuropean Journal of Pediatrics, 1993